The Association between Serum Total Bile Acid Level and Long-Term Prognosis in Patients with Coronary Chronic Total

Xinchun Zeng1, Zhijie Jian2, Shanshan Li1,3,4

  • 1Department of Cardiovascular Medicine, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Disease Markers
|July 5, 2022
PubMed

Insights

Serum total bile acids (TBA) can predict major adverse cardiovascular events (MACE) in patients with coronary chronic artery occlusion (CTO) undergoing percutaneous coronary intervention (PCI). Moderate TBA levels are associated with a reduced risk of MACE.

Area of Science:

  • Cardiology
  • Biochemistry
  • Clinical Medicine

Background:

  • Bile acids are crucial for cholesterol elimination and play a role in coronary artery disease (CAD).
  • Limited research exists on the predictive value of serum total bile acids (TBA) for adverse cardiovascular events in coronary chronic artery occlusion (CTO).

Purpose of the Study:

  • To investigate the relationship between serum TBA levels and long-term prognosis in patients with CTO undergoing percutaneous coronary intervention (PCI).

Main Methods:

  • Serum TBA levels were measured in 613 CTO patients post-PCI.
  • Patients were grouped based on TBA levels (median 3.5 µmol/l and upper normal limit 10 µmol/l).
  • Primary endpoint was all-cause mortality; secondary endpoint was major adverse cardiovascular events (MACE).

Main Results:

  • A moderate TBA level (3.5–10 µmol/l) was associated with a significantly reduced risk of MACE (HR: 0.59, 95% CI: 0.40–0.88) compared to lower levels.
  • TBA levels did not predict all-cause mortality or cardiovascular death.
  • Spline analysis revealed an L-shaped relationship between serum TBA and MACE incidence.

Conclusions:

  • Moderate fasting serum TBA levels possess predictive value for MACE in CTO patients undergoing PCI.
  • This predictive value remains significant after adjusting for clinical and lifestyle risk factors.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
27
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
290
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
534